

# James M Cleary

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1059380/publications.pdf>

Version: 2024-02-01

34  
papers

5,664  
citations

361413

20  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

8478  
citing authors

#	ARTICLE	IF	CITATIONS
1	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	3.0	8
2	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. <i>BMJ Open Sport and Exercise Medicine</i> , 2022, 8, e001353.	2.9	2
3	Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis. <i>JAMA Dermatology</i> , 2021, 157, 119.	4.1	4
4	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	7.0	19
5	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	7.0	23
6	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 27-40.	13.7	1,237
7	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	1.1	13
8	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
9	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.1	194
10	Early TP53 Alterations Shape Gastric and Esophageal Cancer Development. <i>Cancers</i> , 2021, 13, 5915.	3.7	7
11	A woman presenting with an unusual cause of fulminant liver failure and sepsis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101836.	1.5	1
12	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021, 184, 6119-6137.e26.	28.9	201
13	Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. , 2020, 8, e001006.		62
14	Ivosidenib in <i>IDH1</i> -mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020, 21, 796-807.	10.7	620
15	Biomarker-Guided Development of DNA Repair Inhibitors. <i>Molecular Cell</i> , 2020, 78, 1070-1085.	9.7	157
16	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. <i>Investigational New Drugs</i> , 2020, 38, 1483-1494.	2.6	15
17	Safety and activity of ivosidenib in patients with <i>IDH1</i> -mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	8.1	161
18	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2019, 20, 1070-1082.	10.7	169

#	ARTICLE	IF	CITATIONS
19	FOLFOX plus zivâ€afibercept or placebo in firstâ€line metastatic esophagogastric adenocarcinoma: A doubleâ€blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221.	4.1	14
20	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	9.4	392
21	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. <i>Cancer</i> , 2017, 123, 1979-1988.	4.1	92
22	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.	7.0	19
23	Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. <i>British Journal of Cancer</i> , 2017, 117, 1258-1268.	6.4	42
24	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. <i>Nature</i> , 2017, 547, 453-457.	27.8	1,194
25	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	7.0	44
26	Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2510-2510.	1.6	11
27	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	5.0	340
28	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3227-3237.	7.0	85
29	A phase 1 study of ABT-806 in subjects with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 671-678.	2.6	35
30	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	3.7	292
31	A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 937-945.	2.6	57
32	Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 323-326.	4.9	22
33	Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer. <i>Current Oncology Reports</i> , 2010, 12, 87-94.	4.0	54
34	Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. <i>Oncologist</i> , 2009, 14, 1095-1105.	3.7	65